EUCTR2018-000717-20-DE进行中（未招募）1 期
ong-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Medigene AG
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Treated with MDG1011 in a Medigene sponsored clinical trial whether completed or not.
- •- Signed informed consent for this Long-term Follow-up clinical trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who received their last treatment with MDG1011 more than 15 years before the first visit of this Long-term Follow-Up clinical trial
研究者
相似试验
已完成
不适用
ong-term clinical follow-up study of patients and families with choroideremia for future clinical trialsChoroideremiaCHMtapetochoroideal dystrophy (TCD)1001592010010463NL-OMON38958Academisch Medisch Centrum50
尚未招募
不适用
ong term follow up of randomised clinical trial on total joint arthroplasty or trapeziectomie for trapeziometacarpal osteoarthritistrapeziometacarpal osteoarthritiscarpometacarpal osteoarthritis10023213NL-OMON42533Isala Klinieken55
进行中（未招募）
1 期
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapieson-small cell lung cancer (NSCLC), Multiple Myeloma & other indications, Synovial sarcoma, Myxoid/round cell liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864CTIS2024-513033-21-00Adaptimmune LLC76
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-NLGlaxoSmithKline research & development Ltd.171
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-FRGlaxoSmithKline Research & Development Ltd171